iclaprim

DRUG3 trials

Sponsors

Arpida AG, Motif Bio

Conditions

Health-Care-Associated PneumoniaHospital-Acquired PneumoniaSkin Structures and Soft Tissue InfectionsVentilator-Associated Pneumonia

Phase 2

Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia

TerminatedNCT00543608

Arpida AGHealth-Care-Associated Pneumonia, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia

Start: 2007-11-30End: 2009-05-31Target: 135Updated: 2009-02-13

Phase 3

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

CompletedNCT02600611

Motif BioSkin Structures and Soft Tissue Infections

Start: 2015-11-01End: 2017-01-30Updated: 2018-06-19

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2

CompletedNCT02607618

Motif BioSkin Structures and Soft Tissue Infections

Start: 2015-11-30End: 2017-08-08Updated: 2018-08-07

Related Papers

Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.

2018-05-1913 citations

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

Antimicrobial Agents and Chemotherapy2018-03-1237 citations

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1

Clinical Infectious Diseases2017-11-0248 citations